Decision to award Principal Supply Status for permanent coronary drug-eluting stents to Medtronic
- 6 hours ago
- 1 min read
This link will take you to the notification of the decision to award Principal Supply Status for permanent coronary drug-eluting stents (DES) to Medtronic New Zealand Limited (“Medtronic”)
Medtronic’s Resolute Onyx DES will be listed on the Pharmaceutical Schedule and available for Health NZ hospitals at a reduced price from 1 June 2026.
If you need any further information please visit our website.
Ngā mihi
Mikka Nocete | Device Category Manager
______________________________________________________________________
Te Pātaka Whaioranga | Pharmac | PO Box 10-254 | Level 9, 40 Mercer Street, Wellington www.pharmac.govt.nz
